24.65

4.14% 0.98

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $24.65, with a volume of 1.08M. It is up +4.14% in the last 24 hours and down -0.72% over the past month. Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Previous Close:

$23.67

Open:

$23.67

24h Volume:

1.08M

Relative Volume:

0.51

Market Cap:

$2.69B

Revenue:

$71.78M

Net Income/Loss:

$-295.28M

P/E Ratio:

-7.8014

EPS:

-3.1597

Net Cash Flow:

$-271.85M

1W Performance:

+10.99%

1M Performance:

-0.72%

6M Performance:

+45.26%

1Y Performance:

+138.16%

1-Day Range:

$23.61

$25.14

1-Week Range:

$21.23

$24.01

52-Week Range:

$9.14

$28.23

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(415) 660-5320

Address

1600 SIERRA POINT PKWY, BRISBANE

Employee

317

Twitter

Next Earnings Date

null

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	24.65	2.69B	71.78M	-295.28M	-271.85M	-3.1597
VRTX Vertex Pharmaceuticals Inc	510.65	129.43B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	238.64	95.27B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	805.69	82.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.27	53.34B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.62	42.04B	5.76B	514.49M	1.10B	4.4813

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-29-26	Resumed	Oppenheimer	Outperform
Jan-08-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-24-25	Resumed	Truist	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Mar-17-25	Initiated	Leerink Partners	Market Perform
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

01:11 AM

Form 4 Nurix Therapeutics Inc: Julia P. Gregory (Director) For: 14 October - Investing.com Canada

01:11 AM

01:05 AM

Nurix director Gregory sells $528,528 in stock following option exercise By Investing.com - Investing.com Canada

01:05 AM

Oct 14, 2026

Nurix Therapeutics Director Sold Shares Worth Over $528K - TradingView

Oct 14, 2026

A director proposes selling 22,583 Nurix Therapeutics (Nasdaq: NRIX) shares acquired by exercising options. - Stock Titan

Oct 14, 2026

Oct 13, 2026

Form 4 Nurix Therapeutics Inc: Christine Ring (CLO) For: 2 October - Investing.com Canada

Oct 13, 2026

Nurix Therapeutics CLO sells $134k in stock after option exercise - Investing.com UK

Oct 13, 2026

Oct 12, 2026